U
BMRN icon

UBS’s BioMarin Pharmaceuticals BMRN Stock Holding History

UBS’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$43K Buy
600
+400
+200% +$26.3K ﹤0.01% 7017
2014
Q2 		$12K Buy
200
+100
+100% +$6.04K ﹤0.01% 8677
2014
Q1 		$7K Sell
100
-2,000
-95% -$147K ﹤0.01% 9212
2013
Q4 		$148K Buy
2,100
+400
+24% +$27.2K ﹤0.01% 5610
2013
Q3 		$123K Buy
1,700
+1,600
+1,600% +$106K ﹤0.01% 5774
2013
Q2 		$6K Buy
+100
New +$6.23K ﹤0.01% 9094

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's BMRN Position: Q3 2014 in Review

UBS reduced its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q3 2014, selling an estimated $1.91M and leaving 144,235 shares worth $10.4M. The position accounts for 0.01% of the portfolio, ranked #1420.

UBS first reported a position in BMRN in Q2 2013 and has held it in 6 quarters since. The position peaked at $11.9M in Q1 2014. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • UBS held 144,235 shares of BioMarin Pharmaceuticals worth $10.4M as of Q3 2014.
  • UBS sold 29,023 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $1.91M.
  • BioMarin Pharmaceuticals made up 0.01% of UBS's portfolio in Q3 2014, its #1420 holding.
  • UBS first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's BioMarin Pharmaceuticals position peaked at $11.9M in Q1 2014.
  • 316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.